Sign In
Buy HRMY
$35.24
-0.620 (-1.73%)
At Close: Jul 31, 2026
Harmony Biosciences to Participate in Goldman Sachs 46th Annual Global Healthcare Conference
08:05am, Wednesday, 04'th Jun 2025
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the Goldman Sachs 46th
Harmony Biosciences Holdings, Inc. (HRMY) Q1 2025 Earnings Call Transcript
05:05pm, Tuesday, 06'th May 2025
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY ) Q1 2025 Earnings Call May 6, 2025 8:30 AM ET Company Participants Brennan Doyle - Head, Investor Relations Jeffrey Dayno - President and Chief Executi
Harmony Biosciences Holdings, Inc. (HRMY) Tops Q1 Earnings and Revenue Estimates
09:50am, Tuesday, 06'th May 2025
Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.78 per share, beating the Zacks Consensus Estimate of $0.59 per share. This compares to earnings of $0.67 per share a y
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced strong year-over-year revenue growth for WAKIX® of 20% in the first quarter 2025, on its w
Why Harmony Biosciences (HRMY) Could Beat Earnings Estimates Again
01:10pm, Thursday, 01'st May 2025
Harmony Biosciences (HRMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025
08:05am, Tuesday, 29'th Apr 2025
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, before the o
JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play?
08:40am, Monday, 21'st Apr 2025
Both JAZZ and HRMY expect sales from neuroscience products to grow in 2025.
Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome
08:05am, Tuesday, 08'th Apr 2025
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the presentation of updated data from its Open-Label Extension (OLE) study (ZYN2-CL-017) evalu
NEW YORK, NY / ACCESS Newswire / April 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the C
NEW YORK, NY / ACCESS Newswire / April 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the C
NEW YORK, NY / ACCESS Newswire / April 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the C
NEW YORK, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the C
Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors
08:05am, Thursday, 03'rd Apr 2025
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the appointment of Ron Philip to the Company's Board of Directors. Ron Philip is the President
Bronstein, Gewirtz & Grossman, LLC Is Investigating Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Investors to Connect
10:00am, Tuesday, 01'st Apr 2025
NEW YORK, NY / ACCESS Newswire / April 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the C
NEW YORK, NY / ACCESS Newswire / March 31, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Harmony Biosciences Holdings, Inc. ("Harmony" or "the
